drugset / Trial / NCT04954989
Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
Open label and monocentric Phase I Clinical Trial, to Determine the Pharmacokinetics and Pharmacodynamics of Recombinant Human Erythropoietin for Subcutaneous Use in an Adult Male Population
Timeline
- Start
- 2024-10-06
- Primary completion
- 2024-12-01
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 4000 iu | Subcutaneous |
Indications
No indication recorded.